Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 10/20 | 0.50 |
| ▸ | F10 | P00742 | 9/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4714421 | 0.91 | BDKRB1 (0.48) | BDKRB1F10 | |
| SCHEMBL4713469 | 0.89 | BDKRB1 (0.46) | BDKRB1F10 | |
| SCHEMBL4714524 | 0.87 | F10 (0.45) | BDKRB1F10 | |
| SCHEMBL5630738 | 0.81 | BDKRB1 (0.45) | BDKRB1F10 | |
| SCHEMBL4716619 | 0.79 | F10 (0.54) | F10 | |
| SCHEMBL4717800 | 0.79 | BDKRB1 (0.46) | BDKRB1F10 | |
| SCHEMBL4716746 | 0.79 | F10 (0.56) | BDKRB1F10 | |
| SCHEMBL6045057 | 0.78 | BDKRB1 (0.48) | BDKRB1F10 | |
| SCHEMBL4716743 | 0.77 | BDKRB1 (0.59) | BDKRB1F10 | |
| SCHEMBL4712111 | 0.77 | BDKRB1 (0.58) | BDKRB1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | BDKRB1 1/4885F10 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.